This is often achieved through appropriate control of modifiable risk factors, dietary and lifestyle related, optimization of CKD medications such as angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) (15–17), and more recently sodium glucose cotransporter-2 (SGLT2) inhibitors (18, 19). The gene discussed is ACE; the disease is chronic kidney disease.